Myriad Genetics, Inc. (MYGN) Reports In-Line Q2 EPS; Issues FY12 Outlook

August 14, 2012 4:06 PM

Myriad Genetics, Inc. (NASDAQ: MYGN) reported Q2 EPS of $0.34, in-line with the analyst estimate of ...

(Premium-only article. Please sign in or upgrade to SI Premium to view.)

No results found